Skip to main content

Table 2 Gedatolisib partially reversed ABCG2-medaited MDR

From: ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells

Drug

IC50 ± SD1(RF2)

LS180 (μM)

LS180/MX (μΜ)

Mitoxantrone

0.112 ± 0.007 (1.00)

19.235 ± 2.639 (171.74)

+ Gedatolisib (0.1 μM)

0.132 ± 0.007 (1.18)

17.735 ± 2.489 (158.35)

+ Gedatolisib (0.2 μM)

0.109 ± 0.012 (0.97)

14.824 ± 1.112 (132.36)*

+ Ko143 (1 μM)

0.121 ± 0.009 (1.08)

0.616 ± 0.058 (5.5)*

Topotecan

0.098 ± 0.007 (1.00)

25.683 ± 2.031 (262.07)

+ Gedatolisib (0.1 μM)

0.089 ± 0.009 (0.90)

24.583 ± 1.543 (250.85)*

+ Gedatolisib (0.2 μM)

0.087 ± 0.008 (0.89)

18.632 ± 2.332 (190.12)*

+ Ko143 (1 μM)

0.091 ± 0.009 (1.02)

0.319 ± 0.054 (3.58)*

SN-38

0.111 ± 0.010 (1.00)

8.299 ± 0.923 (74.76)

+ Gedatolisib (0.1 μM)

0.107 ± 0.012 (0.96)

6.990 ± 0.777 (62.97)*

+ Gedatolisib (0.2 μM)

0.106 ± 0.011 (0.95)

5.676 ± 0.859 (51.62)*

+ Ko143 (1 μM)

0.112 ± 0.011 (1.01)

0.277 ± 0.031 (2.50)*

Cisplatin

2.511 ± 0.356 (1.00)

2.445 ± 0.390 (0.97)

+ Gedatolisib (0.1 μM)

2.620 ± 0.321 (1.04)

2.214 ± 0.342 (0.88)

+ Gedatolisib (0.2 μM)

2.582 ± 0.323 (1.03)

2.564 ± 0.367 (1.02)

+ Ko143 (1 μM)

2.391 ± 0.398 (0.95)

2.523 ± 0.369 (1.01)

  1. Resistance fold (RF) was calculated from dividing the IC50 values of LS180/MX cells by the IC50 values of LS180 cells in the presence or absence of gedatolisib or Ko143
  2. *Presents when p value is < 0.05. Data was showed with mean ± SD, which is representative for at least three independent experiments